Browsing Tag
Lupin Pharmaceuticals
3 posts
Catalyst Pharmaceuticals (CPRX) agrees $4.1bn buyout as Angelini Pharma plans to enter US rare disease market
Angelini Pharma will pay $4.1 billion for Catalyst Pharmaceuticals at $31.50 a share, but CPRX closed at $31.10. The premium sits in the strategy, not the price.
Lupin Pharmaceuticals gets FDA approval for SOLOSEC sNDA
Lupin Pharmaceuticals has secured approval from the US Food and Drug Administration for its supplemental new drug application…
Lupin Pharmaceuticals signs agreement with Exeltis to promote Solosec in US
Indian pharma company Lupin Pharmaceuticals has signed an agreement with Exeltis USA to promote its antimicrobial drug Solosec…